Monday 2 July 2018

Procalcitonin (PCT) Rapid Test Kit Market Evolving Technology, Trends, New Business Strategy and Industry Analysis to 2017-2022


Procalcitonin (PCT) Rapid Test Kit Market is expected to gain a moderate CAGR growth in the forthcoming period. Procalcitonin is termed as a precursor for calcitonin. CT is secreted by the C-cells of the thyroid after hormonal stimulation whereas, procalcitonin (PCT) can be produced by various cell types and organs after pro-inflammatory stimulation, particularly caused by bacterial challenge. The proportion of PCT concentrations may vary in several age-groups but it can be severe in patients with sepsis or sepsis shock.
The Key Factor That Drives the Growth of Procalcitonin (PCT) Rapid Test Kit Market Research Report by Trends, Applications, Analysis, Growth, and Forecast: 2017 to 2022



Driving factors responsible for the growth of procalcitonin rapid test kit market includes growth in bacterial infection in infants and geriatric population. Also, the rise in case of sepsis and acute sepsis shock adds to the growth of industry. Based on segmentation by product, the procalcitonin rapid test kit market includes time-to-result within 20 and time-to-result within 15. Based on segmentation by end-user, market includes clinical applications and research.

Based on geographical segmentation, the procalcitonin rapid test kit market comprises North America, Latin America, Europe, Asia-Pacific, Middle-East and Africa. North America dominates the market growth owing to rise in bacterial infection in infants and adults. Europe market is also expected to gain a positive growth in the global market owing to rise in medical infrastructure and availability of good medical services. APAC market is also expected to exhibit a higher CAGR growth in the forthcoming period due to rise in medical infrastructure and medical science.


Top Key players include: - Artron, Radiometer Medical, Biopanda Reagents, Roche Diagnostics, Nano-Ditech Corp, BTNX, Green Mountain Biosystems, Vazyme Biotech, BTNX, Operon Bio Tech & Health Care.



No comments:

Post a Comment